nodes	percent_of_prediction	percent_of_DWPC	metapath
Fludarabine—S-Adenosylmethionine—GNMT—liver cancer	0.0157	0.461	CrCbGaD
Fludarabine—Transient ischaemic attack—Sorafenib—liver cancer	0.0146	0.0233	CcSEcCtD
Fludarabine—Myelodysplastic syndrome—Epirubicin—liver cancer	0.0136	0.0216	CcSEcCtD
Fludarabine—Cystitis haemorrhagic—Epirubicin—liver cancer	0.0136	0.0216	CcSEcCtD
Fludarabine—Mucosal inflammation—Sorafenib—liver cancer	0.0133	0.0212	CcSEcCtD
Fludarabine—Myelodysplastic syndrome—Doxorubicin—liver cancer	0.0126	0.02	CcSEcCtD
Fludarabine—Cystitis haemorrhagic—Doxorubicin—liver cancer	0.0126	0.02	CcSEcCtD
Fludarabine—Respiratory distress—Sorafenib—liver cancer	0.0116	0.0185	CcSEcCtD
Fludarabine—Haemoglobin decreased—Sorafenib—liver cancer	0.0107	0.0171	CcSEcCtD
Fludarabine—Tumour lysis syndrome—Epirubicin—liver cancer	0.00982	0.0156	CcSEcCtD
Fludarabine—Adenosine triphosphate—TNK2—liver cancer	0.00968	0.285	CrCbGaD
Fludarabine—DCK—Doxorubicin—Epirubicin—liver cancer	0.00952	0.519	CbGdCrCtD
Fludarabine—Tumour lysis syndrome—Doxorubicin—liver cancer	0.00909	0.0145	CcSEcCtD
Fludarabine—DCK—Epirubicin—Doxorubicin—liver cancer	0.00881	0.481	CbGdCrCtD
Fludarabine—Proteinuria—Sorafenib—liver cancer	0.00839	0.0134	CcSEcCtD
Fludarabine—Protein urine present—Sorafenib—liver cancer	0.00828	0.0132	CcSEcCtD
Fludarabine—Hypocalcaemia—Sorafenib—liver cancer	0.00806	0.0128	CcSEcCtD
Fludarabine—Hyperphosphataemia—Epirubicin—liver cancer	0.00798	0.0127	CcSEcCtD
Fludarabine—Hyperphosphataemia—Doxorubicin—liver cancer	0.00738	0.0118	CcSEcCtD
Fludarabine—Neurotoxicity—Epirubicin—liver cancer	0.00703	0.0112	CcSEcCtD
Fludarabine—Opportunistic infection—Epirubicin—liver cancer	0.00677	0.0108	CcSEcCtD
Fludarabine—Pericardial effusion—Epirubicin—liver cancer	0.00664	0.0106	CcSEcCtD
Fludarabine—Neurotoxicity—Doxorubicin—liver cancer	0.0065	0.0104	CcSEcCtD
Fludarabine—Opportunistic infection—Doxorubicin—liver cancer	0.00626	0.00998	CcSEcCtD
Fludarabine—Pericardial effusion—Doxorubicin—liver cancer	0.00615	0.00979	CcSEcCtD
Fludarabine—Hepatic failure—Sorafenib—liver cancer	0.00596	0.00949	CcSEcCtD
Fludarabine—Cardiac failure congestive—Sorafenib—liver cancer	0.0059	0.00941	CcSEcCtD
Fludarabine—Myelosuppression—Epirubicin—liver cancer	0.00581	0.00926	CcSEcCtD
Fludarabine—Cardiac failure—Sorafenib—liver cancer	0.00549	0.00874	CcSEcCtD
Fludarabine—Myelosuppression—Doxorubicin—liver cancer	0.00538	0.00857	CcSEcCtD
Fludarabine—Dehydration—Sorafenib—liver cancer	0.00498	0.00793	CcSEcCtD
Fludarabine—Mucosal inflammation—Epirubicin—liver cancer	0.00492	0.00784	CcSEcCtD
Fludarabine—Blindness—Epirubicin—liver cancer	0.00492	0.00784	CcSEcCtD
Fludarabine—Toxic epidermal necrolysis—Sorafenib—liver cancer	0.00482	0.00768	CcSEcCtD
Fludarabine—Dysphagia—Sorafenib—liver cancer	0.00463	0.00737	CcSEcCtD
Fludarabine—Blindness—Doxorubicin—liver cancer	0.00456	0.00726	CcSEcCtD
Fludarabine—Mucosal inflammation—Doxorubicin—liver cancer	0.00456	0.00726	CcSEcCtD
Fludarabine—SLC28A3—SLC-mediated transmembrane transport—SLC11A2—liver cancer	0.00445	0.0139	CbGpPWpGaD
Fludarabine—Optic neuritis—Epirubicin—liver cancer	0.00443	0.00706	CcSEcCtD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—SLC9C1—liver cancer	0.00442	0.0138	CbGpPWpGaD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—MYO5B—liver cancer	0.00442	0.0138	CbGpPWpGaD
Fludarabine—Neutropenia—Sorafenib—liver cancer	0.00433	0.00689	CcSEcCtD
Fludarabine—SLC28A3—SLC-mediated transmembrane transport—SLC40A1—liver cancer	0.00425	0.0133	CbGpPWpGaD
Fludarabine—Pneumonia—Sorafenib—liver cancer	0.00415	0.00661	CcSEcCtD
Fludarabine—Optic neuritis—Doxorubicin—liver cancer	0.0041	0.00653	CcSEcCtD
Fludarabine—Stevens-Johnson syndrome—Sorafenib—liver cancer	0.00409	0.00652	CcSEcCtD
Fludarabine—Acute coronary syndrome—Sorafenib—liver cancer	0.00407	0.00648	CcSEcCtD
Fludarabine—Renal failure—Sorafenib—liver cancer	0.00406	0.00646	CcSEcCtD
Fludarabine—Neuropathy peripheral—Sorafenib—liver cancer	0.00404	0.00644	CcSEcCtD
Fludarabine—Myocardial infarction—Sorafenib—liver cancer	0.00404	0.00644	CcSEcCtD
Fludarabine—Bone marrow depression—Epirubicin—liver cancer	0.00404	0.00643	CcSEcCtD
Fludarabine—Stomatitis—Sorafenib—liver cancer	0.00402	0.00641	CcSEcCtD
Fludarabine—Seborrhoeic dermatitis—Epirubicin—liver cancer	0.004	0.00637	CcSEcCtD
Fludarabine—Epistaxis—Sorafenib—liver cancer	0.00389	0.0062	CcSEcCtD
Fludarabine—POLA1—Extension of Telomeres—PCNA—liver cancer	0.00385	0.012	CbGpPWpGaD
Fludarabine—Bone marrow depression—Doxorubicin—liver cancer	0.00374	0.00595	CcSEcCtD
Fludarabine—Haemoglobin—Sorafenib—liver cancer	0.00372	0.00593	CcSEcCtD
Fludarabine—POLA1—Extension of Telomeres—TERT—liver cancer	0.00372	0.0116	CbGpPWpGaD
Fludarabine—Haemorrhage—Sorafenib—liver cancer	0.0037	0.0059	CcSEcCtD
Fludarabine—Seborrhoeic dermatitis—Doxorubicin—liver cancer	0.0037	0.00589	CcSEcCtD
Fludarabine—Haemoptysis—Epirubicin—liver cancer	0.00368	0.00587	CcSEcCtD
Fludarabine—Herpes zoster—Epirubicin—liver cancer	0.00362	0.00577	CcSEcCtD
Fludarabine—POLA1—DNA strand elongation—PCNA—liver cancer	0.00356	0.0111	CbGpPWpGaD
Fludarabine—SLC29A1—Transport of vitamins, nucleosides, and related molecules—ALB—liver cancer	0.00356	0.0111	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—FST—liver cancer	0.00352	0.011	CbGpPWpGaD
Fludarabine—Erythema multiforme—Sorafenib—liver cancer	0.0035	0.00558	CcSEcCtD
Fludarabine—POLA1—E2F mediated regulation of DNA replication—PCNA—liver cancer	0.00347	0.0109	CbGpPWpGaD
Fludarabine—Adenosine triphosphate—AKT1—liver cancer	0.00347	0.102	CrCbGaD
Fludarabine—Haemoptysis—Doxorubicin—liver cancer	0.00341	0.00543	CcSEcCtD
Fludarabine—Herpes zoster—Doxorubicin—liver cancer	0.00335	0.00534	CcSEcCtD
Fludarabine—SLC29A1—SLC-mediated transmembrane transport—SLC11A2—liver cancer	0.00332	0.0104	CbGpPWpGaD
Fludarabine—RRM1—Retinoblastoma (RB) in Cancer—ABL1—liver cancer	0.00331	0.0103	CbGpPWpGaD
Fludarabine—Arrhythmia—Sorafenib—liver cancer	0.00331	0.00527	CcSEcCtD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—SLC9C1—liver cancer	0.0033	0.0103	CbGpPWpGaD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—MYO5B—liver cancer	0.0033	0.0103	CbGpPWpGaD
Fludarabine—Adenosine triphosphate—ABL1—liver cancer	0.00328	0.0965	CrCbGaD
Fludarabine—Alopecia—Sorafenib—liver cancer	0.00327	0.00521	CcSEcCtD
Fludarabine—Malnutrition—Sorafenib—liver cancer	0.00322	0.00514	CcSEcCtD
Fludarabine—SLC29A1—SLC-mediated transmembrane transport—SLC40A1—liver cancer	0.00317	0.0099	CbGpPWpGaD
Fludarabine—Anaemia—Sorafenib—liver cancer	0.00298	0.00475	CcSEcCtD
Fludarabine—Hypocalcaemia—Epirubicin—liver cancer	0.00298	0.00474	CcSEcCtD
Fludarabine—Hyperuricaemia—Epirubicin—liver cancer	0.00294	0.00468	CcSEcCtD
Fludarabine—Leukopenia—Sorafenib—liver cancer	0.00289	0.0046	CcSEcCtD
Fludarabine—POLA1—DNA Replication—PCNA—liver cancer	0.00287	0.00895	CbGpPWpGaD
Fludarabine—RRM1—Retinoblastoma (RB) in Cancer—PCNA—liver cancer	0.00284	0.00887	CbGpPWpGaD
Fludarabine—Cough—Sorafenib—liver cancer	0.00281	0.00448	CcSEcCtD
Fludarabine—Blood uric acid increased—Epirubicin—liver cancer	0.00278	0.00442	CcSEcCtD
Fludarabine—Hypocalcaemia—Doxorubicin—liver cancer	0.00275	0.00439	CcSEcCtD
Fludarabine—Myalgia—Sorafenib—liver cancer	0.00274	0.00437	CcSEcCtD
Fludarabine—Arthralgia—Sorafenib—liver cancer	0.00274	0.00437	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—HNF4A—liver cancer	0.00274	0.00856	CbGpPWpGaD
Fludarabine—Hyperuricaemia—Doxorubicin—liver cancer	0.00272	0.00433	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—HPGDS—liver cancer	0.00269	0.00839	CbGpPWpGaD
Fludarabine—POLA1—DNA Replication Pre-Initiation—PSMD10—liver cancer	0.00268	0.00837	CbGpPWpGaD
Fludarabine—POLA1—DNA Replication Pre-Initiation—PSMA4—liver cancer	0.00268	0.00837	CbGpPWpGaD
Fludarabine—Hyperkalaemia—Epirubicin—liver cancer	0.00268	0.00427	CcSEcCtD
Fludarabine—Anaphylactic shock—Sorafenib—liver cancer	0.00263	0.00419	CcSEcCtD
Fludarabine—Infection—Sorafenib—liver cancer	0.00261	0.00416	CcSEcCtD
Fludarabine—Nervous system disorder—Sorafenib—liver cancer	0.00258	0.00411	CcSEcCtD
Fludarabine—Thrombocytopenia—Sorafenib—liver cancer	0.00258	0.0041	CcSEcCtD
Fludarabine—Blood uric acid increased—Doxorubicin—liver cancer	0.00257	0.00409	CcSEcCtD
Fludarabine—DCK—Retinoblastoma (RB) in Cancer—ABL1—liver cancer	0.00255	0.00796	CbGpPWpGaD
Fludarabine—Anorexia—Sorafenib—liver cancer	0.00251	0.004	CcSEcCtD
Fludarabine—Oesophagitis—Epirubicin—liver cancer	0.00249	0.00397	CcSEcCtD
Fludarabine—Coma—Epirubicin—liver cancer	0.00249	0.00397	CcSEcCtD
Fludarabine—Hyperkalaemia—Doxorubicin—liver cancer	0.00248	0.00395	CcSEcCtD
Fludarabine—Musculoskeletal discomfort—Sorafenib—liver cancer	0.0024	0.00382	CcSEcCtD
Fludarabine—Dyspnoea—Sorafenib—liver cancer	0.00235	0.00374	CcSEcCtD
Fludarabine—POLA1—Synthesis of DNA—PSMD10—liver cancer	0.00234	0.0073	CbGpPWpGaD
Fludarabine—POLA1—Synthesis of DNA—PSMA4—liver cancer	0.00234	0.0073	CbGpPWpGaD
Fludarabine—Dyspepsia—Sorafenib—liver cancer	0.00232	0.00369	CcSEcCtD
Fludarabine—RRM1—E2F transcription factor network—SERPINE1—liver cancer	0.00231	0.00723	CbGpPWpGaD
Fludarabine—Oesophagitis—Doxorubicin—liver cancer	0.0023	0.00367	CcSEcCtD
Fludarabine—Coma—Doxorubicin—liver cancer	0.0023	0.00367	CcSEcCtD
Fludarabine—Phlebitis—Epirubicin—liver cancer	0.0023	0.00366	CcSEcCtD
Fludarabine—Decreased appetite—Sorafenib—liver cancer	0.00229	0.00364	CcSEcCtD
Fludarabine—Gastrointestinal disorder—Sorafenib—liver cancer	0.00227	0.00362	CcSEcCtD
Fludarabine—Fatigue—Sorafenib—liver cancer	0.00227	0.00361	CcSEcCtD
Fludarabine—RRM1—Fluoropyrimidine Activity—TP53—liver cancer	0.00227	0.00709	CbGpPWpGaD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—SLC11A2—liver cancer	0.00226	0.00707	CbGpPWpGaD
Fludarabine—Pain—Sorafenib—liver cancer	0.00225	0.00358	CcSEcCtD
Fludarabine—Constipation—Sorafenib—liver cancer	0.00225	0.00358	CcSEcCtD
Fludarabine—Hepatic failure—Epirubicin—liver cancer	0.0022	0.00351	CcSEcCtD
Fludarabine—POLA1—DNA Replication—PSMD10—liver cancer	0.00219	0.00685	CbGpPWpGaD
Fludarabine—POLA1—DNA Replication—PSMA4—liver cancer	0.00219	0.00685	CbGpPWpGaD
Fludarabine—DCK—Retinoblastoma (RB) in Cancer—PCNA—liver cancer	0.00219	0.00683	CbGpPWpGaD
Fludarabine—Cardiac failure congestive—Epirubicin—liver cancer	0.00218	0.00348	CcSEcCtD
Fludarabine—RRM1—E2F transcription factor network—CDKN2A—liver cancer	0.00216	0.00675	CbGpPWpGaD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—SLC40A1—liver cancer	0.00216	0.00675	CbGpPWpGaD
Fludarabine—Phlebitis—Doxorubicin—liver cancer	0.00212	0.00339	CcSEcCtD
Fludarabine—POLA1—G1/S Transition—PSMA4—liver cancer	0.00211	0.0066	CbGpPWpGaD
Fludarabine—POLA1—G1/S Transition—PSMD10—liver cancer	0.00211	0.0066	CbGpPWpGaD
Fludarabine—Body temperature increased—Sorafenib—liver cancer	0.00208	0.00331	CcSEcCtD
Fludarabine—SLC29A1—Fluoropyrimidine Activity—TP53—liver cancer	0.00207	0.00648	CbGpPWpGaD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—ANXA2—liver cancer	0.00207	0.00647	CbGpPWpGaD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—ATP7B—liver cancer	0.00207	0.00647	CbGpPWpGaD
Fludarabine—Hepatic failure—Doxorubicin—liver cancer	0.00204	0.00325	CcSEcCtD
Fludarabine—Cardiac failure—Epirubicin—liver cancer	0.00203	0.00323	CcSEcCtD
Fludarabine—Cerebrovascular accident—Epirubicin—liver cancer	0.00202	0.00322	CcSEcCtD
Fludarabine—Cardiac failure congestive—Doxorubicin—liver cancer	0.00202	0.00322	CcSEcCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—FST—liver cancer	0.00198	0.0062	CbGpPWpGaD
Fludarabine—Gastrointestinal haemorrhage—Epirubicin—liver cancer	0.00198	0.00315	CcSEcCtD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—NR1H4—liver cancer	0.00196	0.00612	CbGpPWpGaD
Fludarabine—Hypersensitivity—Sorafenib—liver cancer	0.00194	0.00309	CcSEcCtD
Fludarabine—POLA1—S Phase—PSMD10—liver cancer	0.00192	0.00599	CbGpPWpGaD
Fludarabine—POLA1—S Phase—PSMA4—liver cancer	0.00192	0.00599	CbGpPWpGaD
Fludarabine—RRM1—E2F transcription factor network—CDKN1B—liver cancer	0.00191	0.00598	CbGpPWpGaD
Fludarabine—Asthenia—Sorafenib—liver cancer	0.00189	0.00301	CcSEcCtD
Fludarabine—Cardiac failure—Doxorubicin—liver cancer	0.00188	0.00299	CcSEcCtD
Fludarabine—S-Adenosylmethionine—CYP2E1—liver cancer	0.00187	0.0551	CrCbGaD
Fludarabine—Cerebrovascular accident—Doxorubicin—liver cancer	0.00187	0.00298	CcSEcCtD
Fludarabine—POLA1—Retinoblastoma (RB) in Cancer—ABL1—liver cancer	0.00186	0.00583	CbGpPWpGaD
Fludarabine—POLA1—Telomere Maintenance—H2AFX—liver cancer	0.00186	0.00583	CbGpPWpGaD
Fludarabine—Pruritus—Sorafenib—liver cancer	0.00186	0.00297	CcSEcCtD
Fludarabine—Dehydration—Epirubicin—liver cancer	0.00184	0.00293	CcSEcCtD
Fludarabine—Gastrointestinal haemorrhage—Doxorubicin—liver cancer	0.00183	0.00292	CcSEcCtD
Fludarabine—Liver function test abnormal—Epirubicin—liver cancer	0.00183	0.00291	CcSEcCtD
Fludarabine—RRM1—Retinoblastoma (RB) in Cancer—RAF1—liver cancer	0.00181	0.00567	CbGpPWpGaD
Fludarabine—Diarrhoea—Sorafenib—liver cancer	0.0018	0.00287	CcSEcCtD
Fludarabine—Toxic epidermal necrolysis—Epirubicin—liver cancer	0.00178	0.00284	CcSEcCtD
Fludarabine—POLA1—Mitotic G1-G1/S phases—PSMA4—liver cancer	0.00178	0.00556	CbGpPWpGaD
Fludarabine—POLA1—Mitotic G1-G1/S phases—PSMD10—liver cancer	0.00178	0.00556	CbGpPWpGaD
Fludarabine—RRM1—E2F transcription factor network—CDKN1A—liver cancer	0.00177	0.00551	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—ABL1—liver cancer	0.00176	0.00551	CbGpPWpGaD
Fludarabine—POLA1—Telomere Maintenance—PCNA—liver cancer	0.00175	0.00546	CbGpPWpGaD
Fludarabine—Dysphagia—Epirubicin—liver cancer	0.00171	0.00272	CcSEcCtD
Fludarabine—Dehydration—Doxorubicin—liver cancer	0.0017	0.00271	CcSEcCtD
Fludarabine—Liver function test abnormal—Doxorubicin—liver cancer	0.00169	0.00269	CcSEcCtD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—SLC11A2—liver cancer	0.00169	0.00527	CbGpPWpGaD
Fludarabine—POLA1—Telomere Maintenance—TERT—liver cancer	0.00169	0.00527	CbGpPWpGaD
Fludarabine—Vomiting—Sorafenib—liver cancer	0.00167	0.00267	CcSEcCtD
Fludarabine—Angina pectoris—Epirubicin—liver cancer	0.00167	0.00265	CcSEcCtD
Fludarabine—RRM1—Retinoblastoma (RB) in Cancer—CDKN1B—liver cancer	0.00166	0.00519	CbGpPWpGaD
Fludarabine—Rash—Sorafenib—liver cancer	0.00166	0.00264	CcSEcCtD
Fludarabine—Dermatitis—Sorafenib—liver cancer	0.00166	0.00264	CcSEcCtD
Fludarabine—Toxic epidermal necrolysis—Doxorubicin—liver cancer	0.00165	0.00263	CcSEcCtD
Fludarabine—Headache—Sorafenib—liver cancer	0.00165	0.00263	CcSEcCtD
Fludarabine—Bronchitis—Epirubicin—liver cancer	0.00164	0.00262	CcSEcCtD
Fludarabine—Pancytopenia—Epirubicin—liver cancer	0.00162	0.00259	CcSEcCtD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—SLC40A1—liver cancer	0.00161	0.00503	CbGpPWpGaD
Fludarabine—POLA1—Retinoblastoma (RB) in Cancer—PCNA—liver cancer	0.0016	0.005	CbGpPWpGaD
Fludarabine—Neutropenia—Epirubicin—liver cancer	0.0016	0.00255	CcSEcCtD
Fludarabine—Dysuria—Epirubicin—liver cancer	0.0016	0.00255	CcSEcCtD
Fludarabine—Upper respiratory tract infection—Epirubicin—liver cancer	0.00159	0.00253	CcSEcCtD
Fludarabine—RRM1—Retinoblastoma (RB) in Cancer—CCND1—liver cancer	0.00159	0.00495	CbGpPWpGaD
Fludarabine—Dysphagia—Doxorubicin—liver cancer	0.00158	0.00252	CcSEcCtD
Fludarabine—Nausea—Sorafenib—liver cancer	0.00156	0.00249	CcSEcCtD
Fludarabine—POLA1—Chromosome Maintenance—H2AFX—liver cancer	0.00155	0.00485	CbGpPWpGaD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—ANXA2—liver cancer	0.00154	0.00482	CbGpPWpGaD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—ATP7B—liver cancer	0.00154	0.00482	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—HNF4A—liver cancer	0.00154	0.00482	CbGpPWpGaD
Fludarabine—Hyperglycaemia—Epirubicin—liver cancer	0.00154	0.00246	CcSEcCtD
Fludarabine—Angina pectoris—Doxorubicin—liver cancer	0.00154	0.00246	CcSEcCtD
Fludarabine—RRM1—Retinoblastoma (RB) in Cancer—CDKN1A—liver cancer	0.00153	0.00479	CbGpPWpGaD
Fludarabine—Pneumonia—Epirubicin—liver cancer	0.00153	0.00244	CcSEcCtD
Fludarabine—Bronchitis—Doxorubicin—liver cancer	0.00152	0.00242	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—PCNA—liver cancer	0.00151	0.00473	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—HPGDS—liver cancer	0.00151	0.00473	CbGpPWpGaD
Fludarabine—Stevens-Johnson syndrome—Epirubicin—liver cancer	0.00151	0.00241	CcSEcCtD
Fludarabine—Pancytopenia—Doxorubicin—liver cancer	0.0015	0.00239	CcSEcCtD
Fludarabine—Renal failure—Epirubicin—liver cancer	0.0015	0.00239	CcSEcCtD
Fludarabine—Neuropathy peripheral—Epirubicin—liver cancer	0.00149	0.00238	CcSEcCtD
Fludarabine—Stomatitis—Epirubicin—liver cancer	0.00149	0.00237	CcSEcCtD
Fludarabine—Urinary tract infection—Epirubicin—liver cancer	0.00148	0.00236	CcSEcCtD
Fludarabine—Dysuria—Doxorubicin—liver cancer	0.00148	0.00236	CcSEcCtD
Fludarabine—Neutropenia—Doxorubicin—liver cancer	0.00148	0.00236	CcSEcCtD
Fludarabine—POLA1—Synthesis of DNA—PCNA—liver cancer	0.00148	0.00462	CbGpPWpGaD
Fludarabine—Upper respiratory tract infection—Doxorubicin—liver cancer	0.00147	0.00234	CcSEcCtD
Fludarabine—RRM1—E2F transcription factor network—MYC—liver cancer	0.00146	0.00457	CbGpPWpGaD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—NR1H4—liver cancer	0.00146	0.00456	CbGpPWpGaD
Fludarabine—POLA1—Chromosome Maintenance—PCNA—liver cancer	0.00145	0.00454	CbGpPWpGaD
Fludarabine—Haematuria—Epirubicin—liver cancer	0.00145	0.00232	CcSEcCtD
Fludarabine—Epistaxis—Epirubicin—liver cancer	0.00144	0.00229	CcSEcCtD
Fludarabine—Sinusitis—Epirubicin—liver cancer	0.00143	0.00228	CcSEcCtD
Fludarabine—Hyperglycaemia—Doxorubicin—liver cancer	0.00143	0.00227	CcSEcCtD
Fludarabine—Pneumonia—Doxorubicin—liver cancer	0.00142	0.00226	CcSEcCtD
Fludarabine—POLA1—Chromosome Maintenance—TERT—liver cancer	0.0014	0.00439	CbGpPWpGaD
Fludarabine—Stevens-Johnson syndrome—Doxorubicin—liver cancer	0.0014	0.00223	CcSEcCtD
Fludarabine—DCK—Retinoblastoma (RB) in Cancer—RAF1—liver cancer	0.0014	0.00436	CbGpPWpGaD
Fludarabine—POLA1—DNA Replication—PCNA—liver cancer	0.00139	0.00433	CbGpPWpGaD
Fludarabine—Renal failure—Doxorubicin—liver cancer	0.00139	0.00221	CcSEcCtD
Fludarabine—Neuropathy peripheral—Doxorubicin—liver cancer	0.00138	0.0022	CcSEcCtD
Fludarabine—Haemoglobin—Epirubicin—liver cancer	0.00138	0.00219	CcSEcCtD
Fludarabine—Stomatitis—Doxorubicin—liver cancer	0.00138	0.00219	CcSEcCtD
Fludarabine—Urinary tract infection—Doxorubicin—liver cancer	0.00137	0.00218	CcSEcCtD
Fludarabine—Haemorrhage—Epirubicin—liver cancer	0.00137	0.00218	CcSEcCtD
Fludarabine—Hypoaesthesia—Epirubicin—liver cancer	0.00136	0.00217	CcSEcCtD
Fludarabine—Pharyngitis—Epirubicin—liver cancer	0.00136	0.00216	CcSEcCtD
Fludarabine—Haematuria—Doxorubicin—liver cancer	0.00135	0.00214	CcSEcCtD
Fludarabine—POLA1—G1/S Transition—PCNA—liver cancer	0.00134	0.00417	CbGpPWpGaD
Fludarabine—Epistaxis—Doxorubicin—liver cancer	0.00133	0.00212	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—MAPK14—liver cancer	0.00133	0.00415	CbGpPWpGaD
Fludarabine—Sinusitis—Doxorubicin—liver cancer	0.00132	0.00211	CcSEcCtD
Fludarabine—Visual impairment—Epirubicin—liver cancer	0.00132	0.0021	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—ESR1—liver cancer	0.0013	0.00407	CbGpPWpGaD
Fludarabine—POLA1—E2F transcription factor network—SERPINE1—liver cancer	0.0013	0.00407	CbGpPWpGaD
Fludarabine—Erythema multiforme—Epirubicin—liver cancer	0.00129	0.00206	CcSEcCtD
Fludarabine—RRM1—Metabolism—UGDH—liver cancer	0.00128	0.004	CbGpPWpGaD
Fludarabine—DCK—Retinoblastoma (RB) in Cancer—CDKN1B—liver cancer	0.00128	0.004	CbGpPWpGaD
Fludarabine—Haemoglobin—Doxorubicin—liver cancer	0.00127	0.00203	CcSEcCtD
Fludarabine—RRM1—Retinoblastoma (RB) in Cancer—MYC—liver cancer	0.00127	0.00397	CbGpPWpGaD
Fludarabine—Haemorrhage—Doxorubicin—liver cancer	0.00127	0.00202	CcSEcCtD
Fludarabine—Hypoaesthesia—Doxorubicin—liver cancer	0.00126	0.00201	CcSEcCtD
Fludarabine—Pharyngitis—Doxorubicin—liver cancer	0.00126	0.002	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—APC—liver cancer	0.00123	0.00385	CbGpPWpGaD
Fludarabine—Chills—Epirubicin—liver cancer	0.00123	0.00196	CcSEcCtD
Fludarabine—Arrhythmia—Epirubicin—liver cancer	0.00122	0.00195	CcSEcCtD
Fludarabine—Visual impairment—Doxorubicin—liver cancer	0.00122	0.00194	CcSEcCtD
Fludarabine—DCK—Retinoblastoma (RB) in Cancer—CCND1—liver cancer	0.00122	0.00381	CbGpPWpGaD
Fludarabine—POLA1—E2F transcription factor network—CDKN2A—liver cancer	0.00122	0.0038	CbGpPWpGaD
Fludarabine—POLA1—S Phase—PCNA—liver cancer	0.00121	0.00379	CbGpPWpGaD
Fludarabine—Alopecia—Epirubicin—liver cancer	0.00121	0.00193	CcSEcCtD
Fludarabine—RRM1—Metabolism—EPT1—liver cancer	0.0012	0.00376	CbGpPWpGaD
Fludarabine—Erythema multiforme—Doxorubicin—liver cancer	0.0012	0.00191	CcSEcCtD
Fludarabine—Malnutrition—Epirubicin—liver cancer	0.00119	0.0019	CcSEcCtD
Fludarabine—DCK—Retinoblastoma (RB) in Cancer—CDKN1A—liver cancer	0.00118	0.00369	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—TAT—liver cancer	0.00114	0.00356	CbGpPWpGaD
Fludarabine—Chills—Doxorubicin—liver cancer	0.00114	0.00181	CcSEcCtD
Fludarabine—Arrhythmia—Doxorubicin—liver cancer	0.00113	0.0018	CcSEcCtD
Fludarabine—POLA1—Mitotic G1-G1/S phases—PCNA—liver cancer	0.00113	0.00352	CbGpPWpGaD
Fludarabine—Alopecia—Doxorubicin—liver cancer	0.00112	0.00178	CcSEcCtD
Fludarabine—Ill-defined disorder—Epirubicin—liver cancer	0.00111	0.00176	CcSEcCtD
Fludarabine—Malnutrition—Doxorubicin—liver cancer	0.0011	0.00176	CcSEcCtD
Fludarabine—Anaemia—Epirubicin—liver cancer	0.0011	0.00175	CcSEcCtD
Fludarabine—Agitation—Epirubicin—liver cancer	0.00109	0.00174	CcSEcCtD
Fludarabine—POLA1—E2F transcription factor network—CDKN1B—liver cancer	0.00108	0.00337	CbGpPWpGaD
Fludarabine—Malaise—Epirubicin—liver cancer	0.00107	0.00171	CcSEcCtD
Fludarabine—Leukopenia—Epirubicin—liver cancer	0.00107	0.0017	CcSEcCtD
Fludarabine—RRM1—Retinoblastoma (RB) in Cancer—TP53—liver cancer	0.00104	0.00326	CbGpPWpGaD
Fludarabine—Cough—Epirubicin—liver cancer	0.00104	0.00166	CcSEcCtD
Fludarabine—Convulsion—Epirubicin—liver cancer	0.00103	0.00164	CcSEcCtD
Fludarabine—SLC28A3—SLC-mediated transmembrane transport—ALB—liver cancer	0.00102	0.0032	CbGpPWpGaD
Fludarabine—Ill-defined disorder—Doxorubicin—liver cancer	0.00102	0.00163	CcSEcCtD
Fludarabine—POLA1—Retinoblastoma (RB) in Cancer—RAF1—liver cancer	0.00102	0.00319	CbGpPWpGaD
Fludarabine—Anaemia—Doxorubicin—liver cancer	0.00102	0.00162	CcSEcCtD
Fludarabine—Arthralgia—Epirubicin—liver cancer	0.00101	0.00162	CcSEcCtD
Fludarabine—Myalgia—Epirubicin—liver cancer	0.00101	0.00162	CcSEcCtD
Fludarabine—Agitation—Doxorubicin—liver cancer	0.00101	0.00161	CcSEcCtD
Fludarabine—Discomfort—Epirubicin—liver cancer	0.001	0.0016	CcSEcCtD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—CYCS—liver cancer	0.000998	0.00312	CbGpPWpGaD
Fludarabine—Malaise—Doxorubicin—liver cancer	0.000994	0.00158	CcSEcCtD
Fludarabine—POLA1—E2F transcription factor network—CDKN1A—liver cancer	0.000994	0.00311	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—ABL1—liver cancer	0.000994	0.00311	CbGpPWpGaD
Fludarabine—Leukopenia—Doxorubicin—liver cancer	0.000987	0.00157	CcSEcCtD
Fludarabine—DCK—Metabolism—UGDH—liver cancer	0.000985	0.00308	CbGpPWpGaD
Fludarabine—Confusional state—Epirubicin—liver cancer	0.000981	0.00156	CcSEcCtD
Fludarabine—DCK—Retinoblastoma (RB) in Cancer—MYC—liver cancer	0.000979	0.00306	CbGpPWpGaD
Fludarabine—Oedema—Epirubicin—liver cancer	0.000972	0.00155	CcSEcCtD
Fludarabine—Anaphylactic shock—Epirubicin—liver cancer	0.000972	0.00155	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—RAF1—liver cancer	0.000967	0.00302	CbGpPWpGaD
Fludarabine—Infection—Epirubicin—liver cancer	0.000966	0.00154	CcSEcCtD
Fludarabine—Cough—Doxorubicin—liver cancer	0.000962	0.00153	CcSEcCtD
Fludarabine—Convulsion—Doxorubicin—liver cancer	0.000955	0.00152	CcSEcCtD
Fludarabine—Nervous system disorder—Epirubicin—liver cancer	0.000954	0.00152	CcSEcCtD
Fludarabine—Thrombocytopenia—Epirubicin—liver cancer	0.000952	0.00152	CcSEcCtD
Fludarabine—Hyperhidrosis—Epirubicin—liver cancer	0.00094	0.0015	CcSEcCtD
Fludarabine—Myalgia—Doxorubicin—liver cancer	0.000939	0.0015	CcSEcCtD
Fludarabine—Arthralgia—Doxorubicin—liver cancer	0.000939	0.0015	CcSEcCtD
Fludarabine—POLA1—Retinoblastoma (RB) in Cancer—CDKN1B—liver cancer	0.000936	0.00292	CbGpPWpGaD
Fludarabine—Discomfort—Doxorubicin—liver cancer	0.000927	0.00148	CcSEcCtD
Fludarabine—Anorexia—Epirubicin—liver cancer	0.000927	0.00148	CcSEcCtD
Fludarabine—DCK—Metabolism—EPT1—liver cancer	0.000926	0.00289	CbGpPWpGaD
Fludarabine—Confusional state—Doxorubicin—liver cancer	0.000907	0.00145	CcSEcCtD
Fludarabine—Oedema—Doxorubicin—liver cancer	0.0009	0.00143	CcSEcCtD
Fludarabine—Anaphylactic shock—Doxorubicin—liver cancer	0.0009	0.00143	CcSEcCtD
Fludarabine—Infection—Doxorubicin—liver cancer	0.000894	0.00142	CcSEcCtD
Fludarabine—POLA1—Retinoblastoma (RB) in Cancer—CCND1—liver cancer	0.000893	0.00279	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—CDKN1B—liver cancer	0.000886	0.00277	CbGpPWpGaD
Fludarabine—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000886	0.00141	CcSEcCtD
Fludarabine—Nervous system disorder—Doxorubicin—liver cancer	0.000882	0.00141	CcSEcCtD
Fludarabine—Thrombocytopenia—Doxorubicin—liver cancer	0.000881	0.0014	CcSEcCtD
Fludarabine—DCK—Metabolism—TAT—liver cancer	0.000878	0.00274	CbGpPWpGaD
Fludarabine—Paraesthesia—Epirubicin—liver cancer	0.000873	0.00139	CcSEcCtD
Fludarabine—POLA1—Mitotic M-M/G1 phases—PSMD10—liver cancer	0.000873	0.00273	CbGpPWpGaD
Fludarabine—POLA1—Mitotic M-M/G1 phases—PSMA4—liver cancer	0.000873	0.00273	CbGpPWpGaD
Fludarabine—Hyperhidrosis—Doxorubicin—liver cancer	0.00087	0.00139	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—CASP3—liver cancer	0.000868	0.00271	CbGpPWpGaD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—HMOX1—liver cancer	0.000867	0.00271	CbGpPWpGaD
Fludarabine—Dyspnoea—Epirubicin—liver cancer	0.000867	0.00138	CcSEcCtD
Fludarabine—POLA1—Synthesis of DNA—CDKN1B—liver cancer	0.000865	0.0027	CbGpPWpGaD
Fludarabine—POLA1—Retinoblastoma (RB) in Cancer—CDKN1A—liver cancer	0.000864	0.0027	CbGpPWpGaD
Fludarabine—Anorexia—Doxorubicin—liver cancer	0.000858	0.00137	CcSEcCtD
Fludarabine—Dyspepsia—Epirubicin—liver cancer	0.000856	0.00136	CcSEcCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—PCNA—liver cancer	0.000853	0.00266	CbGpPWpGaD
Fludarabine—Decreased appetite—Epirubicin—liver cancer	0.000845	0.00135	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—CCND1—liver cancer	0.000845	0.00264	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—JUN—liver cancer	0.000843	0.00264	CbGpPWpGaD
Fludarabine—Gastrointestinal disorder—Epirubicin—liver cancer	0.00084	0.00134	CcSEcCtD
Fludarabine—Fatigue—Epirubicin—liver cancer	0.000838	0.00134	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—CTNNB1—liver cancer	0.000837	0.00262	CbGpPWpGaD
Fludarabine—Constipation—Epirubicin—liver cancer	0.000832	0.00132	CcSEcCtD
Fludarabine—Pain—Epirubicin—liver cancer	0.000832	0.00132	CcSEcCtD
Fludarabine—POLA1—E2F transcription factor network—MYC—liver cancer	0.000824	0.00258	CbGpPWpGaD
Fludarabine—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.00082	0.00131	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—CDKN1A—liver cancer	0.000818	0.00255	CbGpPWpGaD
Fludarabine—POLA1—DNA Replication—CDKN1B—liver cancer	0.000812	0.00254	CbGpPWpGaD
Fludarabine—Paraesthesia—Doxorubicin—liver cancer	0.000808	0.00129	CcSEcCtD
Fludarabine—DCK—Retinoblastoma (RB) in Cancer—TP53—liver cancer	0.000804	0.00251	CbGpPWpGaD
Fludarabine—Dyspnoea—Doxorubicin—liver cancer	0.000802	0.00128	CcSEcCtD
Fludarabine—Feeling abnormal—Epirubicin—liver cancer	0.000801	0.00128	CcSEcCtD
Fludarabine—POLA1—Synthesis of DNA—CDKN1A—liver cancer	0.000799	0.00249	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—MAPK8—liver cancer	0.000798	0.00249	CbGpPWpGaD
Fludarabine—Dyspepsia—Doxorubicin—liver cancer	0.000792	0.00126	CcSEcCtD
Fludarabine—Decreased appetite—Doxorubicin—liver cancer	0.000782	0.00125	CcSEcCtD
Fludarabine—POLA1—G1/S Transition—CDKN1B—liver cancer	0.000782	0.00244	CbGpPWpGaD
Fludarabine—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000777	0.00124	CcSEcCtD
Fludarabine—Fatigue—Doxorubicin—liver cancer	0.000776	0.00124	CcSEcCtD
Fludarabine—RRM1—Metabolism—CPT1B—liver cancer	0.000775	0.00242	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—GLUL—liver cancer	0.000775	0.00242	CbGpPWpGaD
Fludarabine—Pain—Doxorubicin—liver cancer	0.000769	0.00123	CcSEcCtD
Fludarabine—Constipation—Doxorubicin—liver cancer	0.000769	0.00123	CcSEcCtD
Fludarabine—Body temperature increased—Epirubicin—liver cancer	0.000769	0.00122	CcSEcCtD
Fludarabine—SLC29A1—SLC-mediated transmembrane transport—ALB—liver cancer	0.000764	0.00239	CbGpPWpGaD
Fludarabine—POLA1—DNA Replication—CDKN1A—liver cancer	0.000749	0.00234	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—MAPK14—liver cancer	0.000748	0.00234	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—NR1H4—liver cancer	0.000747	0.00234	CbGpPWpGaD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—CYCS—liver cancer	0.000744	0.00232	CbGpPWpGaD
Fludarabine—POLA1—Mitotic G1-G1/S phases—CDKN2A—liver cancer	0.000744	0.00232	CbGpPWpGaD
Fludarabine—Feeling abnormal—Doxorubicin—liver cancer	0.000741	0.00118	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—VEGFA—liver cancer	0.000737	0.0023	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—GSTA3—liver cancer	0.000735	0.0023	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—ESR1—liver cancer	0.000734	0.00229	CbGpPWpGaD
Fludarabine—POLA1—G1/S Transition—CDKN1A—liver cancer	0.000721	0.00225	CbGpPWpGaD
Fludarabine—Hypersensitivity—Epirubicin—liver cancer	0.000716	0.00114	CcSEcCtD
Fludarabine—POLA1—Retinoblastoma (RB) in Cancer—MYC—liver cancer	0.000716	0.00224	CbGpPWpGaD
Fludarabine—Body temperature increased—Doxorubicin—liver cancer	0.000711	0.00113	CcSEcCtD
Fludarabine—POLA1—S Phase—CDKN1B—liver cancer	0.00071	0.00222	CbGpPWpGaD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—PPARA—liver cancer	0.000701	0.00219	CbGpPWpGaD
Fludarabine—Asthenia—Epirubicin—liver cancer	0.000698	0.00111	CcSEcCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—APC—liver cancer	0.000694	0.00217	CbGpPWpGaD
Fludarabine—Pruritus—Epirubicin—liver cancer	0.000688	0.0011	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—MYC—liver cancer	0.000678	0.00212	CbGpPWpGaD
Fludarabine—POLA1—S Phase—CCND1—liver cancer	0.000677	0.00212	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—TGFB1—liver cancer	0.000676	0.00211	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—GSTA4—liver cancer	0.000672	0.0021	CbGpPWpGaD
Fludarabine—Diarrhoea—Epirubicin—liver cancer	0.000665	0.00106	CcSEcCtD
Fludarabine—Hypersensitivity—Doxorubicin—liver cancer	0.000663	0.00106	CcSEcCtD
Fludarabine—POLA1—Mitotic G1-G1/S phases—CDKN1B—liver cancer	0.000659	0.00206	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—GSTA2—liver cancer	0.000655	0.00205	CbGpPWpGaD
Fludarabine—POLA1—S Phase—CDKN1A—liver cancer	0.000655	0.00205	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle, Mitotic—PSMD10—liver cancer	0.000653	0.00204	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle, Mitotic—PSMA4—liver cancer	0.000653	0.00204	CbGpPWpGaD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—HMOX1—liver cancer	0.000647	0.00202	CbGpPWpGaD
Fludarabine—Asthenia—Doxorubicin—liver cancer	0.000646	0.00103	CcSEcCtD
Fludarabine—Pruritus—Doxorubicin—liver cancer	0.000637	0.00101	CcSEcCtD
Fludarabine—RRM1—Metabolism—GSTA1—liver cancer	0.000632	0.00197	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—TNF—liver cancer	0.000632	0.00197	CbGpPWpGaD
Fludarabine—POLA1—Mitotic G1-G1/S phases—CCND1—liver cancer	0.000628	0.00196	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—KRAS—liver cancer	0.000626	0.00196	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—NAT2—liver cancer	0.000625	0.00195	CbGpPWpGaD
Fludarabine—Vomiting—Epirubicin—liver cancer	0.000618	0.000985	CcSEcCtD
Fludarabine—Diarrhoea—Doxorubicin—liver cancer	0.000616	0.000981	CcSEcCtD
Fludarabine—Rash—Epirubicin—liver cancer	0.000613	0.000977	CcSEcCtD
Fludarabine—Dermatitis—Epirubicin—liver cancer	0.000613	0.000976	CcSEcCtD
Fludarabine—Headache—Epirubicin—liver cancer	0.000609	0.000971	CcSEcCtD
Fludarabine—POLA1—Mitotic G1-G1/S phases—CDKN1A—liver cancer	0.000608	0.0019	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—ALDOB—liver cancer	0.000599	0.00187	CbGpPWpGaD
Fludarabine—POLA1—G1/S Transition—MYC—liver cancer	0.000598	0.00187	CbGpPWpGaD
Fludarabine—DCK—Metabolism—CPT1B—liver cancer	0.000597	0.00186	CbGpPWpGaD
Fludarabine—DCK—Metabolism—GLUL—liver cancer	0.000597	0.00186	CbGpPWpGaD
Fludarabine—POLA1—Mitotic M-M/G1 phases—H2AFX—liver cancer	0.00059	0.00184	CbGpPWpGaD
Fludarabine—POLA1—Retinoblastoma (RB) in Cancer—TP53—liver cancer	0.000588	0.00184	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—PSMD10—liver cancer	0.000584	0.00182	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—PSMA4—liver cancer	0.000584	0.00182	CbGpPWpGaD
Fludarabine—Nausea—Epirubicin—liver cancer	0.000578	0.00092	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—PIK3CA—liver cancer	0.000576	0.0018	CbGpPWpGaD
Fludarabine—DCK—Metabolism—NR1H4—liver cancer	0.000575	0.0018	CbGpPWpGaD
Fludarabine—Vomiting—Doxorubicin—liver cancer	0.000572	0.000911	CcSEcCtD
Fludarabine—RRM1—Metabolism—CRABP1—liver cancer	0.000571	0.00179	CbGpPWpGaD
Fludarabine—Rash—Doxorubicin—liver cancer	0.000567	0.000904	CcSEcCtD
Fludarabine—Dermatitis—Doxorubicin—liver cancer	0.000567	0.000903	CcSEcCtD
Fludarabine—DCK—Metabolism—GSTA3—liver cancer	0.000565	0.00177	CbGpPWpGaD
Fludarabine—Headache—Doxorubicin—liver cancer	0.000564	0.000898	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—TP53—liver cancer	0.000557	0.00174	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—RAF1—liver cancer	0.000545	0.0017	CbGpPWpGaD
Fludarabine—POLA1—S Phase—MYC—liver cancer	0.000543	0.0017	CbGpPWpGaD
Fludarabine—Nausea—Doxorubicin—liver cancer	0.000534	0.000852	CcSEcCtD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—PPARA—liver cancer	0.000522	0.00163	CbGpPWpGaD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—ALB—liver cancer	0.000521	0.00163	CbGpPWpGaD
Fludarabine—DCK—Metabolism—GSTA4—liver cancer	0.000517	0.00162	CbGpPWpGaD
Fludarabine—POLA1—Mitotic G1-G1/S phases—MYC—liver cancer	0.000504	0.00157	CbGpPWpGaD
Fludarabine—DCK—Metabolism—GSTA2—liver cancer	0.000504	0.00157	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—HPGDS—liver cancer	0.0005	0.00156	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—CDKN1B—liver cancer	0.000499	0.00156	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—CASP3—liver cancer	0.000489	0.00153	CbGpPWpGaD
Fludarabine—DCK—Metabolism—GSTA1—liver cancer	0.000486	0.00152	CbGpPWpGaD
Fludarabine—DCK—Metabolism—NAT2—liver cancer	0.000481	0.0015	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—CCND1—liver cancer	0.000476	0.00149	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—JUN—liver cancer	0.000475	0.00148	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—CTNNB1—liver cancer	0.000471	0.00147	CbGpPWpGaD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—RAF1—liver cancer	0.000471	0.00147	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—AKT1—liver cancer	0.00047	0.00147	CbGpPWpGaD
Fludarabine—DCK—Metabolism—ALDOB—liver cancer	0.000461	0.00144	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—CDKN1A—liver cancer	0.000461	0.00144	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—MAPK8—liver cancer	0.00045	0.0014	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—PSMA4—liver cancer	0.000445	0.00139	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—PSMD10—liver cancer	0.000445	0.00139	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle, Mitotic—H2AFX—liver cancer	0.000441	0.00138	CbGpPWpGaD
Fludarabine—DCK—Metabolism—CRABP1—liver cancer	0.00044	0.00137	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—GOT2—liver cancer	0.000433	0.00135	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—VEGFA—liver cancer	0.000415	0.0013	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle, Mitotic—PCNA—liver cancer	0.000413	0.00129	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—CYP2E1—liver cancer	0.000407	0.00127	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—H2AFX—liver cancer	0.000394	0.00123	CbGpPWpGaD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—ALB—liver cancer	0.000388	0.00121	CbGpPWpGaD
Fludarabine—DCK—Metabolism—HPGDS—liver cancer	0.000384	0.0012	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—MYC—liver cancer	0.000382	0.00119	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—CYCS—liver cancer	0.000381	0.00119	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—TGFB1—liver cancer	0.000381	0.00119	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—GOT1—liver cancer	0.000374	0.00117	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—GGT1—liver cancer	0.000374	0.00117	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—PCNA—liver cancer	0.000369	0.00115	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—TERT—liver cancer	0.000357	0.00111	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—TNF—liver cancer	0.000356	0.00111	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—KRAS—liver cancer	0.000353	0.0011	CbGpPWpGaD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—RAF1—liver cancer	0.000351	0.0011	CbGpPWpGaD
Fludarabine—DCK—Metabolism—PSMD10—liver cancer	0.000343	0.00107	CbGpPWpGaD
Fludarabine—DCK—Metabolism—PSMA4—liver cancer	0.000343	0.00107	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—GSTP1—liver cancer	0.000336	0.00105	CbGpPWpGaD
Fludarabine—DCK—Metabolism—GOT2—liver cancer	0.000333	0.00104	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—HMOX1—liver cancer	0.000331	0.00103	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—PIK3CA—liver cancer	0.000324	0.00101	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—TP53—liver cancer	0.000314	0.00098	CbGpPWpGaD
Fludarabine—DCK—Metabolism—CYP2E1—liver cancer	0.000313	0.000979	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—GSTM1—liver cancer	0.000309	0.000964	CbGpPWpGaD
Fludarabine—DCK—Metabolism—CYCS—liver cancer	0.000293	0.000916	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—CYP1A1—liver cancer	0.000293	0.000914	CbGpPWpGaD
Fludarabine—DCK—Metabolism—GOT1—liver cancer	0.000288	0.000899	CbGpPWpGaD
Fludarabine—DCK—Metabolism—GGT1—liver cancer	0.000288	0.000899	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle, Mitotic—CDKN2A—liver cancer	0.000273	0.000852	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—MTHFR—liver cancer	0.000273	0.000852	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—PPARA—liver cancer	0.000268	0.000836	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—AKT1—liver cancer	0.000265	0.000827	CbGpPWpGaD
Fludarabine—DCK—Metabolism—GSTP1—liver cancer	0.000258	0.000807	CbGpPWpGaD
Fludarabine—DCK—Metabolism—HMOX1—liver cancer	0.000255	0.000796	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—CDKN2A—liver cancer	0.000244	0.000762	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle, Mitotic—CDKN1B—liver cancer	0.000242	0.000755	CbGpPWpGaD
Fludarabine—DCK—Metabolism—GSTM1—liver cancer	0.000237	0.000742	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle, Mitotic—CCND1—liver cancer	0.00023	0.00072	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—PIK3CG—liver cancer	0.000229	0.000716	CbGpPWpGaD
Fludarabine—DCK—Metabolism—CYP1A1—liver cancer	0.000225	0.000703	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle, Mitotic—CDKN1A—liver cancer	0.000223	0.000697	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—PPARG—liver cancer	0.000221	0.000691	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—CDKN1B—liver cancer	0.000216	0.000675	CbGpPWpGaD
Fludarabine—DCK—Metabolism—MTHFR—liver cancer	0.00021	0.000656	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—CCND1—liver cancer	0.000206	0.000644	CbGpPWpGaD
Fludarabine—DCK—Metabolism—PPARA—liver cancer	0.000206	0.000643	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—PIK3CD—liver cancer	0.000201	0.000629	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—CDKN1A—liver cancer	0.000199	0.000623	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—ALB—liver cancer	0.000199	0.000621	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle, Mitotic—MYC—liver cancer	0.000185	0.000578	CbGpPWpGaD
Fludarabine—DCK—Metabolism—PIK3CG—liver cancer	0.000176	0.000551	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—PIK3CB—liver cancer	0.000176	0.000549	CbGpPWpGaD
Fludarabine—DCK—Metabolism—PPARG—liver cancer	0.00017	0.000532	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—MYC—liver cancer	0.000165	0.000516	CbGpPWpGaD
Fludarabine—DCK—Metabolism—PIK3CD—liver cancer	0.000155	0.000484	CbGpPWpGaD
Fludarabine—DCK—Metabolism—ALB—liver cancer	0.000153	0.000478	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—TP53—liver cancer	0.000136	0.000424	CbGpPWpGaD
Fludarabine—DCK—Metabolism—PIK3CB—liver cancer	0.000135	0.000422	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—PIK3CA—liver cancer	0.000107	0.000334	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—AKT1—liver cancer	8.74e-05	0.000273	CbGpPWpGaD
Fludarabine—DCK—Metabolism—PIK3CA—liver cancer	8.24e-05	0.000257	CbGpPWpGaD
Fludarabine—DCK—Metabolism—AKT1—liver cancer	6.73e-05	0.00021	CbGpPWpGaD
